Rockville, Md. (December 15, 2021) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics announced today the appointment of W. Allan Alexander, MD as the company’s Chief Medical Officer, effective immediately.
“Allan joining the team is an important milestone for Cellphire,” said Mike Gaffney, Chief Executive Officer. “His deep experience as both a practicing clinician and clinical developer in the hemostatic space will accelerate development and support clinical adoption of our products. We are excited about Allan joining our team as we continue to focus on achieving our vision: saving lives by creating transformative, stabilized cellular therapeutics.”
Dr. Alexander has worked for over 20 years in industry, with experience in all phases of product development from product conception, acquisition, preclinical preparation for regulatory submission, clinical trial design, execution, regulatory negotiation to results dissemination. His work focuses primarily on bridging the gap between the causes of severe bleeding and new, emerging hemostatic therapies. Prior to Cellphire, Dr. Alexander served as Vice President of Medical Affairs for HEMA Biologics, LLC and US WorldMeds, LLC, and served in similar roles at ZymoGenetics, Inc., Sangart, Inc., and CSL Behring, LLC.
About Cellphire Therapeutics:
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications from stopping bleeding, healing wounds, and imaging to targeted drug delivery and regenerative medicine. For more information, visit www.cellphire.com.
The Thrombosomes project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021.
Investor Relations and Media
VP, Strategy & Investor Relations